Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
4(66.7%)
Phase 1
2(33.3%)
6Total
Phase 2(4)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT03608371Phase 2Completed

BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations

Role: lead

NCT03193398Phase 2Completed

BTRX-246040 Administered Once Daily to Patients With Major Depressive Disorder

Role: lead

NCT01798303Phase 2Completed

A Study of LY2940094 in Participants With Alcohol Dependency

Role: lead

NCT01724112Phase 2Completed

Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)

Role: lead

NCT01404091Phase 1Completed

A Study of Nociceptin/Orphanin FQ Peptide Receptor Occupancy in Healthy Subjects

Role: lead

NCT01263236Phase 1Completed

A Study of LY2940094 in Major Depressive Disorder

Role: lead

All 6 trials loaded